Fingolimod Trials Update

Good news from a follow-up on the previously-mentioned fingolimod drug (from Medical News Today 1/10/09

Drug manufacturer Novartis has announced further results from its phase III study of the oral pill fingolimod (FTY-720) in people with relapsing remitting MS.

The results are from a two-year phase III study called FREEDOMS trial and show that the tablet can reduce relapses by up to 60% and disability progression by up to 32% in people with relapsing remitting MS.

The results build on trial data announced earlier in the year that showed a reduction in the number of relapses by about 58% in participants taking fingolimod compared to interferon-beta-1a, a standard injectable therapy for the treatment of relapsing remitting MS.

For more details check it under the Medical News Today link ;)

ps. an update on the progress of Cladribine (the second oral drug used for MS) is also available through the same link for the same date.

Keep up the good spirit! : o)

Advertisements

1 Comment (+add yours?)

  1. Trackback: Cladribine news – timeline « Multiple Sclerosis & Life

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: